MPSYF Stock, Morphosys Ag Ord Information

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest growing drug classes in human healthcare. lt br / gt lt br / gt Together with its partners in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline of drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. lt br / gt lt br / gt Over therapeutic antibody programs based on the company s technologies are currently in development, of which are in clinical trials. The company s most advanced proprietary program is MOR , a first in class antibody against GM CSF for the treatment of rheumatoid arthritis and multiple sclerosis. MOR is part of MorphoSys s collaboration with GlaxoSmithKline. Other proprietary clinical programs include MOR and MOR , both for the treatment of cancer. lt br / gt lt br / gt MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR.